Last reviewed · How we verify
Vortioxetine tablets
Vortioxetine is a serotonin modulator and stimulator that acts as a selective 5-HT3 receptor antagonist, 5-HT1A receptor agonist, 5-HT7 receptor agonist, and norepinephrine reuptake inhibitor.
Vortioxetine is a serotonin modulator and stimulator that acts as a selective 5-HT3 receptor antagonist, 5-HT1A receptor agonist, 5-HT7 receptor agonist, and norepinephrine reuptake inhibitor. Used for Major depressive disorder.
At a glance
| Generic name | Vortioxetine tablets |
|---|---|
| Also known as | Trintellix |
| Sponsor | Takeda |
| Drug class | Serotonin modulator and stimulator |
| Target | 5-HT3 receptor, 5-HT1A receptor, 5-HT7 receptor, norepinephrine transporter |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
This unique mechanism of action allows vortioxetine to modulate the activity of various serotonin receptors and norepinephrine, which contributes to its antidepressant effects. By modulating these receptors, vortioxetine can improve mood, cognition, and other symptoms associated with depression. Additionally, its ability to inhibit norepinephrine reuptake may contribute to its anxiolytic effects.
Approved indications
- Major depressive disorder
Common side effects
- Nausea
- Headache
- Dizziness
- Fatigue
- Dry mouth
Key clinical trials
- A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder (PHASE3)
- Postoperative Pain Management Following Laparoscopic Cholecystectomy (PHASE3)
- A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression
- Vortioxetine for Depressive Symptoms and Freezing of Gait in Parkinson Disease (PHASE4)
- Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia (PHASE2, PHASE3)
- Vortioxetine for the Treatment of Hoarding Disorder (PHASE3)
- Comparison of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Burning Mouth Syndrome (PHASE3)
- Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vortioxetine tablets CI brief — competitive landscape report
- Vortioxetine tablets updates RSS · CI watch RSS
- Takeda portfolio CI